References
- Hauser WA, Annegers JF, Kurland LT. Prevalence of epilepsy in Rochester, Minnesota: 1940–1980. Epilepsia 32(4), 429–445 (1991).
- Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 16(4), 296–304 (2007).
- Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med. 342(5), 314–319 (2000).
- Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 6(9), 793–804 (2007).
- Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 11(2), 56–63 (2011).
- Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92(2–3), 89–124 (2010).
- Hanada T, Hashizume Y, Tokuhara N et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52(7), 1331–1340 (2011).
- Krauss GL, Bar M, Biton V et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol. Scand. 125(1), 8–15 (2012).
- Rektor I, Krauss GL, Bar M et al. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol. Scand. 126(4), 263–269 (2012).
- French JA, Krauss GL, Biton V et al. Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 79(6), 589–596 (2012).
- French JA, Krauss GL, Steinhoff BJ et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia doi:10.1111/j.1528-1167.2012.03638.x (2012) (Epub ahead of print).
- Krauss GL, Perucca E, Ben-Menachem E et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from Phase III, extension study 307. Epilepsia doi:10.1111/j.1528-1167.2012.03648.x (2012) (Epub ahead of print).
- Kew JN, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl.) 179(1), 4–29 (2005).
- Sutula T, He XX, Cavazos J, Scott G. Synaptic reorganization in the hippocampus induced by abnormal functional activity. Science 239(4844), 1147–1150 (1988).
- Mazarati AM, Wasterlain CG. N-methyl-d-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci. Lett. 265(3), 187–190 (1999).
- Mikati MA, Werner S, Gatt A et al. Consequences of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor blockade during status epilepticus in the developing brain. Brain Res. Dev. Brain Res. 113(1–2), 139–142 (1999).